Y-Intercept (HK)’s Structure Therapeutics GPCR Stock Holding History

Y-Intercept (HK)’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$658K	Sell	21,050 -6,523	-24%	-$306K	0.01%	1189
2026 Q2	$1.48M	Buy	+27,573	New	+$1.22M	0.03%	864
2026 Q1	–	Sell	-10,132	Closed	-$705K	–	1750
2025 Q4	$705K	Buy	+10,132	New	+$414K	0.02%	1124
2024 Q4	–	Sell	-40,706	Closed	-$1.79M	–	1369
2024 Q3	$1.79M	Buy	+40,706	New	+$1.57M	0.11%	241
2024 Q2	–	Sell	-4,867	Closed	-$209K	–	1578
2024 Q1	$209K	Buy	+4,867	New	+$205K	0.02%	1137

Other funds holding GPCR

Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return

Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return

Mission Wealth Management Santa Barbara, California $6.32B AUM 20.97% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Wolff Wiese Magana Carslbad, California $218M AUM 37.48% 1-Year Est. Return

Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

Y-Intercept (HK)'s GPCR Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Structure Therapeutics (GPCR) stake by 24% in Q3 2026, selling an estimated $306K and leaving 21,050 shares worth $658K. The position accounts for 0.01% of the portfolio, ranked #1189.

Y-Intercept (HK) first reported a position in GPCR in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.79M in Q3 2024. 13 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

Y-Intercept (HK) held 21,050 shares of Structure Therapeutics worth $658K as of Q3 2026.
Y-Intercept (HK) sold 6,523 Structure Therapeutics shares in Q3 2026, an estimated $306K.
Structure Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1189 holding.
Y-Intercept (HK) first reported a position in Structure Therapeutics in Q1 2024 and has held it in 5 quarters since.
Y-Intercept (HK)'s Structure Therapeutics position peaked at $1.79M in Q3 2024.
13 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.